By Fineline Cube 
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has officially filed for an initial public offering (IPO) with the Hong Kong Stock Exchange. This move marks a significant step in the company’s growth strategy as it seeks to expand its operations and raise capital for further development.
Company Overview and Pipeline
Founded in 2017, Mabwell Bio is a commercial-stage biopharmaceutical company focused on developing drugs for tumors and age-related diseases. The company has a robust product pipeline consisting of more than 10 drugs, showcasing its commitment to innovation and therapeutic advancement.
Distribution Network and Commercialization
Mabwell Bio has established a comprehensive distribution network that covers over 5700 hospitals and institutions across more than 320 cities in China. Its adalimumab biosimilar and denosumab biosimilar are currently under commercialization in China, highlighting the company’s ability to bring innovative treatments to market.-Fineline Info & Tech